478 related articles for article (PubMed ID: 29653649)
1. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Bartels DB; Lip GYH;
Am Heart J; 2018 Apr; 198():55-63. PubMed ID: 29653649
[TBL] [Abstract][Full Text] [Related]
2. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Huisman MV; Lip GY; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Teutsch C; Zint K; Ackermann D; Clemens A; Bartels DB
Am Heart J; 2014 Mar; 167(3):329-34. PubMed ID: 24576516
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.
Mazurek M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Paquette M; Zint K; França LR; Lu S; Bartels DB; Huisman MV; Lip GYH;
Am Heart J; 2019 Dec; 218():123-127. PubMed ID: 31806087
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
Huisman MV; Teutsch C; Lu S; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Lohmann R; Gurusamy VK; Bartels DB; Lip GYH;
Clin Res Cardiol; 2022 May; 111(5):548-559. PubMed ID: 35294623
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.
Lip GYH; Kotalczyk A; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Marler S; Gurusamy VK; Huisman MV;
Clin Res Cardiol; 2022 May; 111(5):560-573. PubMed ID: 35294625
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry.
Bergler-Klein J; Gotcheva N; Kalējs O; Kalarus Z; Kovačić D; Peršić V; Shlyakhto E; Uuetoa T; Huisman MV; Lip GYH; Vinereanu D;
Am J Ther; 2024 Jan-Feb 01; 31(1):e1-e12. PubMed ID: 38231576
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
[TBL] [Abstract][Full Text] [Related]
12. Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation.
Paquette M; Riou França L; Teutsch C; Diener HC; Lu S; Dubner SJ; Ma CS; Rothman KJ; Zint K; Halperin JL; Huisman MV; Lip GYH; Nieuwlaat R
J Am Coll Cardiol; 2017 Sep; 70(13):1573-1583. PubMed ID: 28935034
[TBL] [Abstract][Full Text] [Related]
13. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Chevalier J; Giroud M; de Pouvourville G
Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran for stroke prevention in real life in a sample of population from Turkey: D-SPIRIT registry.
Altın C; Topaloğlu C; Çetin N; Dalgıç O; Yavuz V; Alioğlu E; Bilgin N; Ekmekçi C; Pekel N; Özpelit ME; Tunçer E; Türkoğlu Eİ; Tülüce K; Kocabaş U; Yüksel K; Türk UÖ
Turk Kardiyol Dern Ars; 2021 Dec; 49(8):630-640. PubMed ID: 34881702
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.
Russo V; Bianchi V; Cavallaro C; Vecchione F; De Vivo S; Santangelo L; Sarubbi B; Calabrò P; Nigro G; D'Onofrio A
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(20):3961-7. PubMed ID: 26531286
[TBL] [Abstract][Full Text] [Related]
17. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Graham DJ; Reichman ME; Wernecke M; Hsueh YH; Izem R; Southworth MR; Wei Y; Liao J; Goulding MR; Mott K; Chillarige Y; MaCurdy TE; Worrall C; Kelman JA
JAMA Intern Med; 2016 Nov; 176(11):1662-1671. PubMed ID: 27695821
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
[TBL] [Abstract][Full Text] [Related]
19. Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
Pallisgaard JL; Gislason GH; Torp-Pedersen C; Lee CJ; Sindet-Pedersen C; Staerk L; Olesen JB; Lindhardt TB
PLoS One; 2016; 11(8):e0161768. PubMed ID: 27560967
[TBL] [Abstract][Full Text] [Related]
20. Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).
Fox KAA; Accetta G; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Kayani G; Kakkar AK;
Eur Heart J Qual Care Clin Outcomes; 2018 Jan; 4(1):27-35. PubMed ID: 28950344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
